Abstract
OBJECTIVE: To evaluate the effects of oral and intravenous Iron on serum ferritin and total Iron binding
capacity in patients of chronic renal failure receiving recombinant human erythropoietin.
METHODOLOGY: This prospective comparative interventional study was conducted in the Department
of Pharmacology and Therapeutics LUMHS Jamshoro with the collaboration of Urology Department of
Liaquat University Hospital (LUH) Jamshoro and Hyderabad, for the duration of 6 months after approval
from research ethics committee of the institute. By using Rao software sampling calculator and after
following inclusion and exclusion criteria 80 patients were taken and divided into two groups, Group A
(Oral Iron+rHuEPO) & Group B (I/V Iron+rHuEPO). Informed consent was taken from all patients. Serum
ferritin & TIBC were done at the beginning and at the end of the six months. Data was analyzed on SPSS
version 16.0 (IBM, Incorporation, USA). The continuous variables were analyzed by student’s t-test. The
significant p-value was taken at ≤ 0.05.
RESULTS: Significant statistical improvement was observed in Serum Ferritin and TIBC of both Groups
(Group A and Group B). But there is more prominent improvement in serum ferritin and TIBC of Group B
(I/V iron + rHuEPO). No adverse effects of iron therapy and erythropoietin therapy were observed in
patients of both groups.
CONCLUSION: The present study concludes that treatment with I/V Iron + Erythropoietin therapy
significantly improves Serum Ferritin and TIBC of CRF patients of Group B who received Intravenous
Iron Dextran 2ml diluted in 200ml normal saline twice a month + rHuEPO 2000 IU SC twice a week.
Sadat Memon, Nasreen Qazi, Shafiq ur Rehman Memon, Jamil Laghari. (2019) Comparative Study of Oral versus Intravenous Iron Therapy in Patients of Chronic Renal Failure Receiving Recombinant Human Erythropoietin, Journal of Liaquat University of Medical and Health Sciences, Volume-18, Issue-1.
-
Views
541 -
Downloads
48
Article Details
Volume
Issue
Type
Language
